Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ffect profile, mean that, if approved, satraplatin will represent an important new therapy option for patients with advanced prostate cancer whose prior chemotherapy has failed."

The relative risk of disease progression favored satraplatin for all pre- specified patient subsets, including prior Taxotere use, geographies, and the presence or absence of pain. For each of the 20 subsets presented today, the reduction in relative risk of disease progression ranged from 26% to 46%, corresponding to hazard ratios between 0.74 and 0.54.

Disease progression in the SPARC trial was defined as the first occurrence of any of several types of progression, including radiologic tumor progression (RECIST for soft tissue lesions or two or more new lesions on a bone scan); skeletal-related events (including a bone fracture, bone surgery or initiation of bisphosphonates); symptomatic progression (pain, weight loss, worsening of performance status); or death from any cause. Approximately 37% of patients in the trial progressed by pain and approximately 36% progressed on radiologic evidence. The hazard ratio for PFS for the subset of patients with pain progression or death was 0.64 (95% CI: 0.51-0.79, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients with radiologic progression or death was 0.64 (95% CI: 0.51-0.81, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients who progressed in ways other than radiologic or pain progression was 0.86 (95% CI: 0.63-1.17, p > 0.05).

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. As previously communicated, the interim analysis for overall survival conducted in June 2006 showed a trend, although not statistically si
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary ... announced on May 22 the actions that Ranbaxy ... conduct under prior management ( ... to support Ranbaxy in its efforts to address ... led to the investigations by the U.S. Department ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... 22, 2013 Cedars-Sinai Heart Institute is honoring ... pioneer in modern mitral heart valve repair, Alain ... Corday, MD, International Prize in Heart Research. The ... recognize physicians and scientists conducting groundbreaking research, or ... medicine. , Carpentier is a leading ...
(Date:5/22/2013)... A new study provides neurobiological evidence for ... in people with insomnia, which may have implications ... , "Insomnia has been consistently identified as a ... Franzen, PhD, an assistant professor of psychiatry at ... in the brain circuitry underlying emotion regulation may ...
(Date:5/22/2013)... May 22, 2013 Digital Advertising Agency, ... behalf of its social media management client, Primal ... year's supply of the all-natural organic deodorant. The contest ... of the rapidly-growing start-up deodorant company based in Tampa, ... contest or sweepstakes on a Facebook page is a ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 DiscountFurnaceFilter.com ... quality merchandise ranging from furnace filters, dehumidifiers, fans, ... is excited to add Stadler Form's product line ... summer product line (fans, aroma diffusers and dehumidifiers) ... Form’s Otto Fan is the perfect combination of ...
(Date:5/22/2013)... York, NY and Troy, NY (PRWEB) May 22, ... Medicine at Mount Sinai and Rensselaer Polytechnic Institute ... educational programs, research, and development of new diagnostic ... alliance was commemorated in a signing ceremony on ... initiative to use their expertise—Rensselaer’s in engineering and ...
Breaking Medicine News(10 mins):Health News:Heart valve repair innovator receives Cedars-Sinai Heart Institute's Corday Prize in Heart Research 2Health News:Study shows that insomnia may cause dysfunction in emotional brain circuitry 2Health News:Social Media Management Firm, 21Digital, Launches National Facebook Sweepstakes for Client, Primal Pit Paste 2Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 3Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 4Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 5Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 6Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 7
... Oct. 24 CME LLC (http://www.CMELLC.com ), ... programs,since 1978, today announced it has been granted ... as an approved sponsor of,continuing medical education for ... full approval as part of the APA,s,Continuing Education ...
... developed a new type of biodegradable nanoparticle. The ... makes it easier to target tumour tissue. These ... release of anticancer drugs. Rijcken recently gained her ... , Anticancer drugs sometimes have very harmful side ...
... used to be dogma that the brain was shut away ... outside forces of nature. But thats not how it is ... of Kevin Tracey, MD, it turns out that the brain ... the bodys inflammatory response to infection and autoimmune diseases. Understanding ...
... University of Liverpool have found that 73% of avian ... the initial infected farm, but larger outbreaks are more ... team from the Universitys Faculty of Veterinary Science and ... of Environment, Food and Rural Affairs (DEFRA) to produce ...
... Disease, ROCKVILLE, Md., Oct. 24 EntreMed, ... developing,therapeutics for the treatment of cancer and inflammatory ... Phase 2, open-label study for,Panzem(R) NCD (2ME2 or ... presented by Dr. Daniela Matei, principal investigator for,the ...
... Calif., Oct. 24 Anesiva,Inc. (Nasdaq: ANSV ) ... the markets close on Thursday, November 1, 2007 and ... day. Members of Anesiva,s,management team will discuss financial results ... overview of the company,s product pipeline, recent,events and milestones. ...
Cached Medicine News:Health News:CME LLC Granted Five-Year Full Approval by the American Psychological Association 2Health News:Nanoballs deliver drugs 2Health News:Scientists discover a direct route from the brain to the immune system 2Health News:Large avian flu outbreaks more likely to involve duck meat industry, experts find 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 3Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 4Health News:Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: